AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17382027 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with chemotherapy
Number of subjects: 0
Study 17382027 — intervention group
Group type: EXPERIMENTAL
Intervention: Small molecule inhibitors targeting VEGF receptor and tyrosine kinase receptor combined with standard chemotherapy
Number of subjects: 0
Study 15126020 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplements (lemon-flavored cod liver oil and children's multivitamin-mineral with selenium)
Number of subjects: 4
Study 11641299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid and heparin
Number of subjects: 15
Study 11641299 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 15
Study 11641299 — intervention group
Group type: COMPARATOR
Intervention: Saline and heparin
Number of subjects: 15
Study 11641299 — intervention group
Group type: COMPARATOR
Intervention: Saline with intralipid and heparin
Number of subjects: 15
Study 9825068 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 227
Study 9825068 — intervention group
Group type: COMPARATOR
Intervention: Cloxacillin
Number of subjects: 227
Study 8129390 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CDDP 75 mg/m2 i.v. day 1 or 20 mg/m2 i.v. day 1, 2, 4, 5; MMC 10 mg/m2 i.v. day 1; etoposide 50 mg/body i.v. day 3, 4, 5; 5'-DFUR 2,100 mg/body po 4 day/week)
Number of subjects: 7
Study 2530998 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium 0.15 mg kg‐1
Number of subjects: 41
Study 2530998 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium 0.20 mg kg‐1
Number of subjects: 41
Study 2530998 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium 0.25 mg kg‐1
Number of subjects: 41
Study 2530998 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 1.0 mg kg‐1
Number of subjects: 41
Study 2530998 — intervention group
Group type: EXPERIMENTAL
Intervention: atracurium 0.5 mg kg‐1
Number of subjects: 41
Study 2530998 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium
Number of subjects: 41
Study 2530998 — intervention group
Group type: EXPERIMENTAL
Intervention: atracurium
Number of subjects: 41
Study 2530998 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium (higher doses)
Number of subjects: 41
Study 1173736 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary milk with lactase preparation
Number of subjects: 3
Study 1173736 — intervention group
Group type: COMPARATOR
Intervention: Lactose-free milk
Number of subjects: 3
Study 1173736 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary milk
Number of subjects: 3
Study 31397943 — intervention group
Group type: EXPERIMENTAL
Intervention: bleselumab 50 mg
Number of subjects: 50
Study 31397943 — intervention group
Group type: EXPERIMENTAL
Intervention: bleselumab 100 mg
Number of subjects: 50
Study 31397943 — intervention group
Group type: EXPERIMENTAL
Intervention: bleselumab 200 mg
Number of subjects: 50
Study 31397943 — intervention group
Group type: EXPERIMENTAL
Intervention: bleselumab 500 mg
Number of subjects: 50
Study 31397943 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 29710295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin, 100 mg 3 times a day for 5 days (n=255)
Number of subjects: 513
Study 29710295 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin, single 3-g dose (n=258)
Number of subjects: 513
Study 28063345 — intervention group
Group type: EXPERIMENTAL
Intervention: VPAN program (Physical Activity and Nutrition program)
Number of subjects: 214
Study 28063345 — intervention group
Group type: EXPERIMENTAL
Intervention: Education sessions (part of the VPAN program)
Number of subjects: 214
Study 26316344 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue-type plasminogen activator plus endovascular therapy (Solitaire device)
Number of subjects: 195
Study 26316344 — intervention group
Group type: COMPARATOR
Intervention: tissue-type plasminogen activator alone
Number of subjects: 195
Study 23597719 — intervention group
Group type: EXPERIMENTAL
Intervention: RV3-BB rotavirus vaccine (8.3×10(6)FFU/mL)
Number of subjects: 60
Study 23597719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21172479 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletonized left internal mammary artery
Number of subjects: 200
Study 21172479 — intervention group
Group type: COMPARATOR
Intervention: Pedicled left internal mammary artery
Number of subjects: 200
Study 21172479 — intervention group
Group type: COMPARATOR
Intervention: Pedicled harvesting
Number of subjects: 200
Study 21172479 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative echocardiographic results and clinical and angiographic outcomes
Number of subjects: 200
Study 18296987 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer (Walk4Life LS‐7010)
Number of subjects: 102
Study 16553812 — intervention group
Group type: EXPERIMENTAL
Intervention: MenC/P64k vaccine
Number of subjects: 20
Study 16553812 — intervention group
Group type: COMPARATOR
Intervention: Commercial polysaccharide vaccine AC
Number of subjects: 20
Study 12393737 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care after SCT
Number of subjects: 90
Study 10354806 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A individuals
Number of subjects: 0
Study 10354806 — intervention group
Group type: COMPARATOR
Intervention: Type B individuals
Number of subjects: 0
Study 8834630 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood PMNs at rest
Number of subjects: 24
Study 8834630 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood PMNs stimulated
Number of subjects: 24
Study 8834630 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinically healthy persons) at rest
Number of subjects: 24
Study 8834630 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinically healthy persons) stimulated
Number of subjects: 24
Study 8834630 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary sinus PMNs at rest
Number of subjects: 24
Study 8834630 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary sinus PMNs stimulated
Number of subjects: 24
Study 8834630 — intervention group
Group type: EXPERIMENTAL
Intervention: H2O2 generation by rest PMNs from coronary sinus
Number of subjects: 24
Study 8834630 — intervention group
Group type: EXPERIMENTAL
Intervention: H2O2 generation by PMA stimulated PMNs
Number of subjects: 24
Study 1980911 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5ASA)
Number of subjects: 86
Study 1980911 — intervention group
Group type: COMPARATOR
Intervention: Salazosulphapyridine (SASP)
Number of subjects: 86
Study 7369159 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinfandel wine
Number of subjects: 6
Study 7369159 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous ethanol solution
Number of subjects: 6
Study 7369159 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized Zinfandel wine
Number of subjects: 6
Study 7369159 — intervention group
Group type: COMPARATOR
Intervention: Deionized water
Number of subjects: 6
Study 31392363 — intervention group
Group type: COMPARATOR
Intervention: Vaginal estrogen treatment
Number of subjects: 0
Study 31392363 — intervention group
Group type: COMPARATOR
Intervention: Estrogen-only or combination systemic HRT
Number of subjects: 0
Study 31392363 — intervention group
Group type: EXPERIMENTAL
Intervention: Local estrogen treatment (LET)
Number of subjects: 0
Study 30053284 — intervention group
Group type: EXPERIMENTAL
Intervention: Slimming World (SW) program with low energy-dense (LED) meals
Number of subjects: 96
Study 30053284 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC) program with high energy-dense (HED) meals
Number of subjects: 96
Study 28069521 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Faces Pain Scale (S-FPS)
Number of subjects: 180
Study 28069521 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Concrete Ordinal Scale (S-COS)
Number of subjects: 180
Study 28069521 — intervention group
Group type: COMPARATOR
Intervention: Faces Pain Scale-Revised (FPS-R)
Number of subjects: 180
Study 28069521 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation (Face Legs Activity Cry Consolability)
Number of subjects: 180
Study 26321708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 43
Study 26321708 — intervention group
Group type: COMPARATOR
Intervention: HAIC
Number of subjects: 43
Study 26321708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib therapy
Number of subjects: 43
Study 26321708 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer treatment period of sorafenib
Number of subjects: 43
Study 23909782 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal inlay removal
Number of subjects: 10
Study 21370962 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention (SDMI)
Number of subjects: 212
Study 21370962 — intervention group
Group type: COMPARATOR
Intervention: Treatment decision-making as usual (Control)
Number of subjects: 212
Study 18694479 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counselling on physical activity and diet at five routine visits to a PHN and supervised group exercise until 37 weeks' gestation or ten months postpartum
Number of subjects: 132
Study 18694479 — intervention group
Group type: COMPARATOR
Intervention: Control clinics continued their usual care
Number of subjects: 132
Study 16552744 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery (da Vinci Surgical System)
Number of subjects: 50
Study 16552744 — intervention group
Group type: COMPARATOR
Intervention: Standard laparoscopic fundoplication
Number of subjects: 50
Study 16552744 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 12746751 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control
Number of subjects: 4
Study 12746751 — intervention group
Group type: COMPARATOR
Intervention: Rhythm control
Number of subjects: 4
Study 10902993 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy supplement (E) = 1171 kJ + 12 mg iron
Number of subjects: 136
Study 10902993 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplement (M) = 12 mg iron + 209 kJ
Number of subjects: 136
Study 10902993 — intervention group
Group type: COMPARATOR
Intervention: Control (S) = 104 kJ
Number of subjects: 136
Study 9151070 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 37
Study 9151070 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol-sorbitol chewing gum
Number of subjects: 37
Study 9151070 — intervention group
Group type: COMPARATOR
Intervention: Unsweetened chewing gum base (Control)
Number of subjects: 37
Study 7963139 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (100 or 600 mg daily for 58 days)
Number of subjects: 0
Study 7963139 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro studies of ascorbic acid
Number of subjects: 0
Study 3597142 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic irradiation followed by a prostatic boost
Number of subjects: 453
Study 3597142 — intervention group
Group type: COMPARATOR
Intervention: Prostate irradiation only
Number of subjects: 453
Study 3597142 — intervention group
Group type: EXPERIMENTAL
Intervention: Total doses to the prostate of more than 7000 cGy
Number of subjects: 453
Study 3597142 — intervention group
Group type: EXPERIMENTAL
Intervention: AP/PA irradiation of the pelvic lymphatics
Number of subjects: 453
Study 29109047 — intervention group
Group type: EXPERIMENTAL
Intervention: Anapen autoinjector
Number of subjects: 30
Study 29109047 — intervention group
Group type: COMPARATOR
Intervention: Prefilled syringe (25.4-mm needle)
Number of subjects: 30
Study 29109047 — intervention group
Group type: EXPERIMENTAL
Intervention: Anapen autoinjector in overweight women
Number of subjects: 30
Study 26933849 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (80 mg/m²) plus carboplatin (AUC 6) for six cycles
Number of subjects: 692
Study 26933849 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m²) plus carboplatin (AUC 6) every 3 weeks for six cycles
Number of subjects: 692
Study 26933849 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (80 mg/m²) plus carboplatin (AUC 6) for six cycles among patients not receiving bevacizumab
Number of subjects: 692
Study 26933849 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m²) plus carboplatin (AUC 6) every 3 weeks for six cycles among patients not receiving bevacizumab
Number of subjects: 692
Study 26933849 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (80 mg/m²) plus carboplatin (AUC 6) for six cycles among patients receiving bevacizumab
Number of subjects: 692
Study 26933849 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m²) plus carboplatin (AUC 6) every 3 weeks for six cycles among patients receiving bevacizumab
Number of subjects: 692
Study 26933849 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel
Number of subjects: 692
Study 23594060 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based psychoeducational program (average of 36.7 hours over 6 months)
Number of subjects: 159
Study 23594060 — intervention group
Group type: COMPARATOR
Intervention: Mailed information (provided to all dyads for 12 months)
Number of subjects: 159
Study 21450567 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT; 85-90% of peak oxygen uptake, VO(2peak))
Number of subjects: 200
Study 21450567 — intervention group
Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT; 50-60% of VO(2peak))
Number of subjects: 200
Study 21450567 — intervention group
Group type: COMPARATOR
Intervention: Recommendation of Regular Exercise (RE)
Number of subjects: 200
Study 21450567 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 200
Study 21450567 — intervention group
Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 200
Study 20935337 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial physical activity group (diet and physical activity for 12 months)
Number of subjects: 130
Study 20935337 — intervention group
Group type: COMPARATOR
Intervention: Delayed physical activity group (diet for 12 months, physical activity delayed for 6 months)
Number of subjects: 130
Study 20935337 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (initial and delayed physical activity)
Number of subjects: 130
Study 20935337 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial physical activity group
Number of subjects: 130
Study 18405787 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg/d, n=132)
Number of subjects: 263
Study 18405787 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg/d, n=131)
Number of subjects: 263
Study 18405787 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril plus diuretics
Number of subjects: 263
Study 18405787 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine plus diuretics
Number of subjects: 263
Study 18405787 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite secondary end point
Number of subjects: 263
Study 15660392 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (180 microg once weekly for 48 weeks)
Number of subjects: 121
Study 15660392 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 121
Study 15660392 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Number of subjects: 121
Study 11912091 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon autograft
Number of subjects: 70
Study 11912091 — intervention group
Group type: COMPARATOR
Intervention: Hamstring tendon autograft
Number of subjects: 70
Study 11912091 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 9661633 — intervention group
Group type: EXPERIMENTAL
Intervention: NIS gene expression in primary thyroid carcinomas
Number of subjects: 41
Study 9661633 — intervention group
Group type: EXPERIMENTAL
Intervention: NIS gene expression in follicular thyroid adenomas
Number of subjects: 41
Study 9661633 — intervention group
Group type: EXPERIMENTAL
Intervention: NIS mRNA expression in metastasis
Number of subjects: 41
Study 9661633 — intervention group
Group type: EXPERIMENTAL
Intervention: NIS gene expression in differentiated thyroid cancer patients with metastases
Number of subjects: 41
Study 7662936 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary early intervention pilot programme for back injuries
Number of subjects: 250
Study 7662936 — intervention group
Group type: COMPARATOR
Intervention: Control wards (1395 nurses)
Number of subjects: 250
Study 2757695 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone administration
Number of subjects: 0
Study 2757695 — intervention group
Group type: COMPARATOR
Intervention: Control (no naloxone)
Number of subjects: 0
Study 3961 — intervention group
Group type: EXPERIMENTAL
Intervention: cedilanid-D
Number of subjects: 15
Study 3961 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 7017171 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg cinoxacin
Number of subjects: 50
Study 7017171 — intervention group
Group type: COMPARATOR
Intervention: 1 g nalidixic acid 4 times daily
Number of subjects: 50
Study 31104069 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombomodulin (0.06 mg/kg/d, maximum 6 mg/d) administered as an intravenous bolus or a 15-minute infusion once daily for 6 days (n = 395)
Number of subjects: 800
Study 31104069 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 405)
Number of subjects: 800
Study 31104069 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombomodulin (n = 396)
Number of subjects: 800
Study 31104069 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 404)
Number of subjects: 800
Study 29162361 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance tests (OGTTs) with 25, 75, and 125 g glucose
Number of subjects: 16
Study 29162361 — intervention group
Group type: COMPARATOR
Intervention: Isoglycemic glucose infusions (IIGI)
Number of subjects: 16
Study 26859828 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiation at CD4 counts of 350‐550 cells/mm³
Number of subjects: 85
Study 26859828 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiation at lower CD4 cell counts
Number of subjects: 85
Study 26859828 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline viral load and less education
Number of subjects: 85
Study 24423245 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus brief education (intervention)
Number of subjects: 184
Study 24423245 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 184
Study 22687887 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based multiple computer-tailored smoking cessation program
Number of subjects: 1123
Study 22687887 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1123
Study 19439041 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue factor pathway inhibitor (rTFPI)
Number of subjects: 0
Study 17319797 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg etomoxir
Number of subjects: 350
Study 17319797 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg etomoxir
Number of subjects: 350
Study 17319797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 15144667 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine granules (0.5 g.kg(‐1).d(‐1) for 7 days)
Number of subjects: 120
Study 15144667 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycine)
Number of subjects: 120
Study 12492461 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer touch-screen technology for self-reporting psychosocial information
Number of subjects: 450
Study 12492461 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of Cancer Needs Questionnaire (CNQ)
Number of subjects: 450
Study 12492461 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of EORTC QLQ-C30
Number of subjects: 450
Study 12492461 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of Beck Depression Inventory - Short Form (BDI)
Number of subjects: 450
Study 12492461 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-item pen and paper survey for assessing acceptability
Number of subjects: 450
Study 9661544 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 40
Study 9661544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9661544 — intervention group
Group type: COMPARATOR
Intervention: No intervention (patients without pulmonary hypertension)
Number of subjects: 40
Study 7655808 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainee-centered training on QI methods with problem-solving oriented methodology (GI)
Number of subjects: 30
Study 7655808 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional training (GII)
Number of subjects: 30
Study 7655808 — intervention group
Group type: COMPARATOR
Intervention: No training (GIII)
Number of subjects: 30
Study 2577460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide (10 mg daily)
Number of subjects: 22000
Study 2577460 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg daily)
Number of subjects: 22000
Study 2577460 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg daily)
Number of subjects: 22000
Study 2577460 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol (160 mg)
Number of subjects: 22000
Study 769697 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 1% solution or cream formulation
Number of subjects: 1361
Study 769697 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1361
Study 31846073 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional crown (test)
Number of subjects: 40
Study 31846073 — intervention group
Group type: COMPARATOR
Intervention: Standard healing abutment (control)
Number of subjects: 40
Study 30795492 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone adjunct therapy for 24 weeks
Number of subjects: 93
Study 30795492 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone adjunct therapy for 52 weeks
Number of subjects: 93
Study 30795492 — intervention group
Group type: COMPARATOR
Intervention: Risperidone adjunct therapy for 0 weeks
Number of subjects: 93